Declaring that it is “determined to grow its portfolio in the complex generics space,” Novartis generics division Sandoz announced its acquisition of device device developer Coalesce Product Development. Coalesce’s inhaler technology include MDI, breath-actuated MDI, and DPI platforms. Sandoz said that it “sees respiratory as a key pillar of its ambitious long-term growth strategy and intends to actively explore further opportunities both in-house and externally.”
Sandoz’s current respiratory products include the AirFluSal Forspiro fluticasone propionate / salmeterol DPI, which is approved in Europe as well as in Mexico and South Korea. In January 2020, Sandoz discontinued development of its generic fluticasone propionate / salmeterol DPI for the US market. The company acquired distribution rights to an authorized generic of Proventil HFA albuterol MDI from Kindeva Drug Delivery in March 2021, and in June 2021, the FDA approved the company’s ANDA for its generic albuterol MDI. Sandoz also launched an authorized generic of Emergent BioSolution’s Narcan nasal spray in December 2021.
Sandoz CEO Richard Saynor commented, “Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity. At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients.”
Read the Sandoz press release.
